European responses to the Ebola crisis- Part I: Initiatives at the European Medicines Agency (EMA)

Research output: Other contributionNet publication - Internet publicationResearch

Standard

European responses to the Ebola crisis- Part I: Initiatives at the European Medicines Agency (EMA). / Minssen, Timo.

2014Blog "Bill of Health".

Research output: Other contributionNet publication - Internet publicationResearch

Harvard

Minssen, T 2014, European responses to the Ebola crisis- Part I: Initiatives at the European Medicines Agency (EMA)..

APA

Minssen, T. (2014, Nov 12). European responses to the Ebola crisis- Part I: Initiatives at the European Medicines Agency (EMA).

Vancouver

Minssen T. European responses to the Ebola crisis- Part I: Initiatives at the European Medicines Agency (EMA). 2014.

Author

Minssen, Timo. / European responses to the Ebola crisis- Part I: Initiatives at the European Medicines Agency (EMA). 2014.

Bibtex

@misc{0ab50c341b254177b16545f3ac6733b8,
title = "European responses to the Ebola crisis- Part I: Initiatives at the European Medicines Agency (EMA)",
abstract = "While it is evident that the current Ebola crisis requires both immediate responses and more sustainable changes in health care policy, research and regulation, medicines regulators are collaborating internationally to find innovative solutions for enhancing the evaluation of and access to potential new medicines to counter Ebola outbreaks. In a statement announced by the International Coalition of Medicines Regulatory Authorities (ICMRA) in September 2014, regulators around the world led by the FDA and the EMA have vowed to collaborate in supporting accelerated evaluation of experimental new drugs to treat Ebola virus infections and say they will encourage submission of regulatory dossiers. This clearly backs up the World Health Organization’s (WHO) decision to test experimental Ebola treatments in infected patients in the current outbreak region in West Africa and to speed up the development of vaccines.In part 1 of this blog-series I summarize and discuss some of the recent European responses to the current crisis starting with an overview on recent initiatives at the EMA.",
keywords = "Faculty of Law, Ebola, legal and regulatory responses challenges, global responses",
author = "Timo Minssen",
year = "2014",
month = "11",
day = "12",
language = "English",
type = "Other",

}

RIS

TY - ICOMM

T1 - European responses to the Ebola crisis- Part I: Initiatives at the European Medicines Agency (EMA)

AU - Minssen, Timo

PY - 2014/11/12

Y1 - 2014/11/12

N2 - While it is evident that the current Ebola crisis requires both immediate responses and more sustainable changes in health care policy, research and regulation, medicines regulators are collaborating internationally to find innovative solutions for enhancing the evaluation of and access to potential new medicines to counter Ebola outbreaks. In a statement announced by the International Coalition of Medicines Regulatory Authorities (ICMRA) in September 2014, regulators around the world led by the FDA and the EMA have vowed to collaborate in supporting accelerated evaluation of experimental new drugs to treat Ebola virus infections and say they will encourage submission of regulatory dossiers. This clearly backs up the World Health Organization’s (WHO) decision to test experimental Ebola treatments in infected patients in the current outbreak region in West Africa and to speed up the development of vaccines.In part 1 of this blog-series I summarize and discuss some of the recent European responses to the current crisis starting with an overview on recent initiatives at the EMA.

AB - While it is evident that the current Ebola crisis requires both immediate responses and more sustainable changes in health care policy, research and regulation, medicines regulators are collaborating internationally to find innovative solutions for enhancing the evaluation of and access to potential new medicines to counter Ebola outbreaks. In a statement announced by the International Coalition of Medicines Regulatory Authorities (ICMRA) in September 2014, regulators around the world led by the FDA and the EMA have vowed to collaborate in supporting accelerated evaluation of experimental new drugs to treat Ebola virus infections and say they will encourage submission of regulatory dossiers. This clearly backs up the World Health Organization’s (WHO) decision to test experimental Ebola treatments in infected patients in the current outbreak region in West Africa and to speed up the development of vaccines.In part 1 of this blog-series I summarize and discuss some of the recent European responses to the current crisis starting with an overview on recent initiatives at the EMA.

KW - Faculty of Law

KW - Ebola, legal and regulatory responses challenges, global responses

M3 - Net publication - Internet publication

ER -

ID: 127237528